ISIN | LU0115986761 |
---|---|
Valor Number | 1113164 |
Bloomberg Global ID | |
Fund Name | RH&P Global Life Sciences Fund A CAP USD |
Fund Provider |
RH&PARTNER Investment Funds
Basel, Switzerland Phone: +41 61 378 83 63 E-Mail: info@rh-finanz.ch Web: https://www.rh-finanz.ch |
Fund Provider | RH&PARTNER Investment Funds |
Representative in Switzerland |
ACOLIN Fund Services AG Zürich Phone: +41 44 396 96 96 |
Distributor(s) |
Banque Pictet & Cie SA
Credit Suisse Zürich UBS n/a Vontobel n/a |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | N/A |
Peculiarities |
Current Price * | 169.11 USD | 18.11.2024 |
---|---|---|
Previous Price * | 170.24 USD | 15.11.2024 |
52 Week High * | 188.29 USD | 08.11.2024 |
52 Week Low * | 150.21 USD | 28.11.2023 |
NAV * | 169.11 USD | 18.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 61,638,260 | |
Unit/Share Assets *** | 58,436,021 | |
Trading Information SIX |
YTD Performance | +0.91% |
29.12.2023 - 18.11.2024
29.12.2023 18.11.2024 |
---|---|---|
YTD Performance (in CHF) | +6.02% |
29.12.2023 - 18.11.2024
29.12.2023 18.11.2024 |
1 month | -8.20% |
18.10.2024 - 18.11.2024
18.10.2024 18.11.2024 |
3 months | -9.62% |
19.08.2024 - 18.11.2024
19.08.2024 18.11.2024 |
6 months | +0.19% |
20.05.2024 - 18.11.2024
20.05.2024 18.11.2024 |
1 year | +11.65% |
20.11.2023 - 18.11.2024
20.11.2023 18.11.2024 |
2 years | -1.03% |
18.11.2022 - 18.11.2024
18.11.2022 18.11.2024 |
3 years | -6.76% |
18.11.2021 - 18.11.2024
18.11.2021 18.11.2024 |
5 years | +0.52% |
18.11.2019 - 18.11.2024
18.11.2019 18.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Charles River Laboratories International Inc | 4.53% | |
---|---|---|
Bio-Techne Corp | 4.46% | |
Nektar Therapeutics | 4.36% | |
Illumina Inc | 3.93% | |
Exelixis Inc | 3.87% | |
Alkermes PLC | 3.72% | |
IQVIA Holdings Inc | 3.65% | |
Biogen Inc | 3.59% | |
Amgen Inc | 3.57% | |
Incyte Corp | 3.53% | |
Last data update | 30.04.2021 |
TER *** | 2.40% |
---|---|
TER date *** | 30.06.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.40% |
Ongoing Charges *** | 2.29% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |